Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study-Reference-Cited by-同舟云学术

Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study

Published:2014-10-10 Issue:2 Volume:64 Page:243-249
ISSN:0017-5749
Container-title:Gut
language:en
Short-container-title:Gut

Author:

Danese Silvio,Rudziński Janusz,Brandt Wolfgang,Dupas Jean-Louis,Peyrin-Biroulet Laurent,Bouhnik Yoram,Kleczkowski Dariusz,Uebel Peter,Lukas Milan,Knutsson Mikael,Erlandsson Fredrik,Hansen Mark Berner,Keshav Satish

Publisher

BMJ

Subject

Gastroenterology

Reference21 articles.

1. Ulcerative colitis;Danese;N Engl J Med,2011

2. The impact of ulcerative colitis on patients’ lives compared to other chronic diseases: a patient survey;Rubin;Dig Dis Sci,2010

3. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health;Peyrin-Biroulet;Gut,2012

4. Vedolizumab as induction and maintenance therapy for ulcerative colitis;Feagan;N Engl J Med,2013

5. Review article: the role of anti-TNF in the management of ulcerative colitis – past, present and future;Danese;Aliment Pharmacol Ther,2013

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetically Proxied Interleukin‐13 Inhibition Is Associated With Risk of Psoriatic Disease: A Mendelian Randomization Study;Arthritis & Rheumatology;2024-07-31

2. Strategies for targeting cytokines in inflammatory bowel disease;Nature Reviews Immunology;2024-03-14

3. Recent advances in bacteria‐based platforms for inflammatory bowel diseases treatment;Exploration;2024-03-05

4. Risk of Infection in Patients With Inflammatory Bowel Disease Treated With Interleukin-Targeting Agents: A Systematic Review and Meta-Analysis;Inflammatory Bowel Diseases;2024-03-01

5. Fibrosis in IBD: from pathogenesis to therapeutic targets;Gut;2024-01-17